睿知中国医院研究地图
候选清单

即将招募淋巴瘤未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06788600,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically diagnosed as relapsed or refractory EBV-positive lymphoma (confirmed by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) showing EBER positivity in tumor tissue) that has failed standard treatment and lacks effective treatment options. This includes, but is not limited to, NK/T-cell lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), or other Peripheral T-cell Lymphomas (PTCL).Relapse is defined as the appearance of new lesions in the primary site or elsewhere after achieving complete remission (CR).

    入选标准第 2 条

  3. Less than 4 weeks since the last anti-tumor treatment (radiotherapy, chemotherapy, targeted therapy, immunotherapy, or local-regional therapy) or less than 2 weeks since palliative radiotherapy; patients with treatment-related adverse reactions (excluding hair loss) from previous anti-tumor therapy that have not recovered to NCI CTCAE ≤ 1 level.

    排除标准第 11 条

    Major surgery within 4 weeks prior to screening (catheter placement or small biopsies as required by the protocol are not exclusion criteria), or if the impact of surgery or trauma has not resolved within 14 days prior to enrollment.

    排除标准第 19 条

  4. No use of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human erythropoietin, recombinant human thrombopoietin, or blood component transfusion within 14 days prior to screening. Hemoglobin ≥80 g/L; neutrophil count >1.0 × 10\^9/L; platelet count ≥75 × 10\^9/L.

    入选标准第 8 条

    Total bilirubin ≤1.5× upper limit of normal (ULN); if liver metastasis or Gilbert's syndrome present, total bilirubin ≤3× ULN.

    入选标准第 9 条

    ALT or AST ≤2.5× ULN; if liver metastasis, ALT or AST ≤5× ULN.

    入选标准第 10 条

    Serum creatinine (SCr) ≤1.5× ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault formula).

    入选标准第 11 条

    Prothrombin time (PT), International Normalized Ratio (INR) ≤1.5× ULN (unless using warfarin for anticoagulation).

    入选标准第 12 条

    HCVAb positive, with HCV RNA ≥ ULN at the study center.

    排除标准第 23 条

  5. A lymph node lesion with a maximum long diameter >15 mm on enhanced CT, MRI, or PET-CT.

    入选标准第 6 条

  6. Any active autoimmune disease or history of autoimmune diseases, including but not limited to immune-related neurological diseases, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barré syndrome, myasthenia gravis, systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, autoimmune hepatitis, toxic epidermal necrolysis (TEN), or Stevens-Johnson syndrome (except for Type 1 diabetes managed with stable doses of insulin).

    排除标准第 5 条

    Known infections with hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), or syphilis, or positive screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), HIV antibody, or treponemal antibody (TP) at screening:

    排除标准第 21 条

    HBsAg(+) or HBcAb(+), with HBV DNA copy number ≥2000 IU/mL (or above the lower limit of positive detection at the study center);

    排除标准第 22 条

  7. Pregnant or breastfeeding women.

    排除标准第 25 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06788600,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male or female patients aged 18 to 75 years (inclusive).
  2. Histologically or cytologically diagnosed as relapsed or refractory EBV-positive lymphoma (confirmed by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) showing EBER positivity in tumor tissue) that has failed standard treatment and lacks effective treatment options. This includes, but is not limited to, NK/T-cell lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), or other Peripheral T-cell Lymphomas (PTCL).Relapse is defined as the appearance of new lesions in the primary site or elsewhere after achieving complete remission (CR).
  3. Relapsed/Refractory DLBCL: Must have received at least second-line systemic therapy.
  4. Relapsed/Refractory Peripheral T-cell Lymphoma: Must have received at least first-line systemic therapy.
  5. Relapsed/Refractory NK/T-cell Lymphoma: Must have received a regimen based on L-asparaginase (I/II stage diseases as per the nasal NK/T-cell lymphoma CA staging system must have also received radiotherapy).
  6. A lymph node lesion with a maximum long diameter >15 mm on enhanced CT, MRI, or PET-CT.
  7. An extranodal lesion with a maximum long diameter >10 mm. 6.Adequate organ function as evidenced by the following criteria:
  8. No use of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human erythropoietin, recombinant human thrombopoietin, or blood component transfusion within 14 days prior to screening. Hemoglobin ≥80 g/L; neutrophil count >1.0 × 10\^9/L; platelet count ≥75 × 10\^9/L.
  9. Total bilirubin ≤1.5× upper limit of normal (ULN); if liver metastasis or Gilbert's syndrome present, total bilirubin ≤3× ULN.
  10. ALT or AST ≤2.5× ULN; if liver metastasis, ALT or AST ≤5× ULN.
  11. Serum creatinine (SCr) ≤1.5× ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault formula).
  12. Prothrombin time (PT), International Normalized Ratio (INR) ≤1.5× ULN (unless using warfarin for anticoagulation).
  13. Cardiac Doppler ultrasound evaluation: Left ventricular ejection fraction (LVEF) ≥50%.
  14. If the investigator considers any of the above parameters below the study's lower limit due to disease progression, the patient's inclusion can be discussed with the sponsor and the CRO's medical team.

排除标准:Exclusion Criteria:

  1. **Exclusion Criteria**
  2. Patients with a history of other tumors, except for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, in situ cervical cancer, gastrointestinal mucosal carcinoma, or other malignancies considered acceptable by the investigator, provided these were treated and have not recurred within the last 5 years.
  3. Known to have aggressive NK-cell leukemia; central nervous system (CNS) lymphoma or CNS metastases; or associated hemophagocytic syndrome.
  4. Known to have poorly controlled cardiac clinical symptoms or diseases, such as NYHA Class II heart failure or higher (see Appendix 4, section 16.4), unstable angina, myocardial infarction within the past 6 months, or clinically significant and treatable supraventricular or ventricular arrhythmias.
  5. Any active autoimmune disease or history of autoimmune diseases, including but not limited to immune-related neurological diseases, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barré syndrome, myasthenia gravis, systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, autoimmune hepatitis, toxic epidermal necrolysis (TEN), or Stevens-Johnson syndrome (except for Type 1 diabetes managed with stable doses of insulin).
  6. Any uncontrolled clinical disease (e.g., respiratory, circulatory, digestive, neurological, hematological, urogenital, endocrine diseases) or mental illness (e.g., depression, schizophrenia) or other significant illnesses that, in the investigator's assessment, could hinder informed consent, interfere with the interpretation of trial results, pose risks to the subject from participation, or otherwise affect the trial's objectives.
  7. History of interstitial lung disease or suspected interstitial lung disease; or presence of pulmonary abnormalities that may interfere with the detection or management of potential drug-related pulmonary toxicity during the trial.
  8. Allergies to the investigational drug (including any excipients). A history of severe allergic reactions to any drugs, foods, or vaccines, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, or local allergic necrotizing reactions (Arthus reactions).
  9. Any abnormalities at the injection site or permanent body art (e.g., tattoos) that the investigator believes may hinder observation of local reactions at the injection site.
  10. Contraindications to intramuscular injection (see Appendix 5, section 16.5).
  11. Less than 4 weeks since the last anti-tumor treatment (radiotherapy, chemotherapy, targeted therapy, immunotherapy, or local-regional therapy) or less than 2 weeks since palliative radiotherapy; patients with treatment-related adverse reactions (excluding hair loss) from previous anti-tumor therapy that have not recovered to NCI CTCAE ≤ 1 level.
  12. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation.
  13. Systemic treatment with corticosteroids (>10 mg/day of prednisone or equivalent dose of other glucocorticoids) or other immunosuppressants within 14 days prior to the first dose of vaccine. However, inhaled or local use of steroids and adrenal hormone replacement at doses ≤10 mg/day of prednisone in the absence of active autoimmune disease is permitted.
  14. Receipt of an mRNA vaccine or similar nanoparticle delivery drugs (e.g., LNP) within 6 months prior to the first dose of vaccine.
  15. Receipt of live vaccines, attenuated live vaccines, or inactivated vaccines within 4 weeks prior to the first dose of vaccine.
  16. Previous administration of therapeutic vaccines or cellular immunotherapy for anti-tumor treatment.
  17. Participation in other clinical trials of drugs or devices within 3 months prior to screening.
  18. Blood donation or significant blood loss (>450 mL) within 3 months prior to screening.
  19. Major surgery within 4 weeks prior to screening (catheter placement or small biopsies as required by the protocol are not exclusion criteria), or if the impact of surgery or trauma has not resolved within 14 days prior to enrollment.
  20. History of substance abuse or known medical, psychological, or social conditions, such as a history of alcohol or drug abuse.
  21. Known infections with hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), or syphilis, or positive screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), HIV antibody, or treponemal antibody (TP) at screening:
  22. HBsAg(+) or HBcAb(+), with HBV DNA copy number ≥2000 IU/mL (or above the lower limit of positive detection at the study center);
  23. HCVAb positive, with HCV RNA ≥ ULN at the study center.
  24. Patients with active tuberculosis (TB) (those suspected of having active TB must undergo chest X-ray, sputum tests, and exclude active TB through clinical symptoms and signs) or a history of active TB; or severe acute or chronic infections requiring systemic treatment.
  25. Pregnant or breastfeeding women.
  26. Any other factors that the investigator believes make the subject unsuitable for participation in this trial.

引自 ClinicalTrials.gov, NCT06788600, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06788600,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06788600